Alaunos Therapeutics Dirección
Dirección controles de criterios 3/4
El CEO de Alaunos Therapeutics es Dale Hogue, nombrado en Jan 2024, tiene una permanencia de menos de un año. posee directamente un 0.25% de las acciones de la empresa, con un valor de $9.56K. La antigüedad media del equipo directivo y de la junta directiva es de 3 años y 3.9 años, respectivamente.
Información clave
Dale Hogue
Chief Executive Officer (CEO)
US$11.1k
Compensación total
Porcentaje del salario del CEO | n/a |
Permanencia del CEO | less than a year |
Participación del CEO | 0.2% |
Permanencia media de la dirección | 3yrs |
Promedio de permanencia en la Junta Directiva | 3.9yrs |
Actualizaciones recientes de la dirección
Recent updates
Health Check: How Prudently Does Alaunos Therapeutics (NASDAQ:TCRT) Use Debt?
Nov 10Alaunos wins bullish view at Wells Fargo on promise of cell therapy technology
Oct 04Alaunos posts 51% tumor reduction for lung cancer therapy
Sep 21Alaunos sheds 52% ahead of data readout for T-cell therapy platform
Sep 15Alaunos Therapeutics: Keep An Eye On Upcoming TCR-T Solid Tumor Study Data
Aug 31Alaunos Therapeutics GAAP EPS of -$0.05 beats by $0.02
Aug 15Is Alaunos Therapeutics (NASDAQ:TCRT) Weighed On By Its Debt Load?
Jul 26Is Alaunos Therapeutics (NASDAQ:TCRT) Using Debt Sensibly?
Apr 06Is ZIOPHARM Oncology (NASDAQ:ZIOP) A Risky Investment?
Dec 20Ziopharm: Waiting On FYE 2021 For Further Clinical Data On TCR-T/CAR-T Therapies
Jun 19ZIOPHARM records sharpest gain in nearly four months
Jun 09Will ZIOPHARM Oncology (NASDAQ:ZIOP) Spend Its Cash Wisely?
May 11ZIOPHARM Oncology, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 07How Much Of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Do Institutions Own?
Mar 09We're Hopeful That ZIOPHARM Oncology (NASDAQ:ZIOP) Will Use Its Cash Wisely
Jan 15ZioPharm highlights upcoming catalysts, says current cash runway into mid-2022
Jan 14Ziopharm Oncology to test non-viral CAR-T in leukemia and lymphoma patients
Dec 21Activist holder wins Ziopharm Oncology board seats
Dec 17Ziopharm Oncology CFO to step down
Dec 14What Is The Ownership Structure Like For ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)?
Nov 23Ziopharm says WaterMill’s nominees lack experience, White Rock backs proposal on board reconstitution
Nov 20ZIOPHARM Oncology, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 06Ziopharm Oncology thumbs down on investor's call for board seats
Nov 02CEO
Dale Hogue (54 yo)
less than a year
Permanencia
US$11,090
Compensación
Mr. Dale Curtis Hogue, Jr. is Director of Alaunos Therapeutics, Inc. from December 29, 2023 and also serves as Interim Chief Executive Officer from January 20, 2024. Mr. Hogue has worked in various roles...
Equipo directivo
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
Interim CEO & Director | less than a year | US$11.09k | 0.25% $ 9.6k | |
Senior VP of Legal | 3yrs | US$701.74k | sin datos | |
Vice President of Finance & Principal Accounting Officer | 3.2yrs | sin datos | sin datos |
3.0yrs
Permanencia media
47yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de TCRT se considera experimentado (3 años antigüedad media).
Miembros de la Junta
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
Interim CEO & Director | less than a year | US$11.09k | 0.25% $ 9.6k | |
Independent Chairman of the Board | 3.9yrs | US$900.26k | 0.076% $ 2.9k | |
Chairman of Scientific Advisory Board | 4.4yrs | sin datos | sin datos | |
Independent Director | 3.9yrs | US$103.26k | 0.97% $ 37.0k | |
Member of Scientific Advisory Board | 4.2yrs | sin datos | sin datos | |
Member of Scientific Advisory Board | 4.2yrs | sin datos | sin datos | |
Independent Director | 1.7yrs | US$84.01k | 0% $ 0 | |
Independent Director | 3.8yrs | US$104.26k | 0.52% $ 19.8k | |
Member of Scientific Advisory Board | no data | sin datos | sin datos |
3.9yrs
Permanencia media
58yo
Promedio de edad
Junta con experiencia: La junta directiva de TCRT se considera experimentada (3.9 años de antigüedad promedio).